AlloVir Inc (NASDAQ:ALVR) shares are trading higher Wednesday after the company announced the U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy designation to its lead investigational multi-virus-specific T cell therapy, posoleucel.
The posoleucel designation is for the prevention of clinically significant infections and disease from six devastating viruses that commonly impact high-risk adult and pediatric patients following allogeneic hematopoietic cell transplants: adenovirus, BK virus, cytomegalovirus, Epstein-Barr virus, human herpes virus-6 and JC virus.
